Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDALIST Asian bridging study of luspatercept in lower-risk MDS with ring sideroblasts
CTR20210622Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Mar 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept in myelodysplastic syndrome (MDS), anaemia, sponsored by Celgene Corporation. Started Mar 2022; status: active.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on CTR20210622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210622.